Novo Nordisk has positive trial results for oral GLP-1 drug, shares jump

Reuters

COPENHAGEN (Reuters) - Danish drugmaker Novo Nordisk, the world's biggest insulin maker, said on Friday it had received positive results from a phase 2 trial of an oral version of a long-acting GLP-1 for treatment of people with type 2 diabetes. GLP-1 (Glucagon-like peptide-1) drugs work by stimulating the release of insulin when blood-sugar levels become too low. Shares in Novo Nordisk, the biggest listed company in the Nordics measured by market capitalization, rose around 4 percent following the news. (This story corrects headline to oral GLP-1 drug) (Reporting by Ole Mikkelsen. Editing by Jane Merriman)